WG
CABA icon

Winton Group’s Cabaletta Bio CABA Stock Holding History

Winton Group’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84K Buy
27,000
+11,700
+76% +$38.5K ﹤0.01% 1100
2026
Q1 		$41.2K Buy
+15,300
New +$42.5K ﹤0.01% 1069

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Winton Group's CABA Position: Q2 2026 in Review

Winton Group increased its Cabaletta Bio (CABA) stake by 76% in Q2 2026, buying an estimated $38.5K and bringing the position to 27,000 shares worth $84K. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

Winton Group first reported a position in CABA in Q1 2026 and has held it in 2 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Winton Group held 27,000 shares of Cabaletta Bio worth $84K as of Q2 2026.
  • Winton Group bought 11,700 Cabaletta Bio shares in Q2 2026, an estimated $38.5K.
  • Cabaletta Bio made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1100 holding.
  • Winton Group first reported a position in Cabaletta Bio in Q1 2026 and has held it in 2 quarters since.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.